Gilder Gagnon Howe & Co. LLC Buys 18,351 Shares of BioNTech SE Sponsored ADR $BNTX

Gilder Gagnon Howe & Co. LLC raised its stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 2.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 667,635 shares of the company’s stock after purchasing an additional 18,351 shares during the quarter. Gilder Gagnon Howe & Co. LLC’s holdings in BioNTech were worth $71,083,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. BNP Paribas Financial Markets grew its holdings in BioNTech by 6.7% during the second quarter. BNP Paribas Financial Markets now owns 1,275,475 shares of the company’s stock worth $135,800,000 after buying an additional 80,005 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in BioNTech by 58.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,108,719 shares of the company’s stock valued at $118,045,000 after acquiring an additional 410,351 shares in the last quarter. Dodge & Cox purchased a new position in BioNTech during the 2nd quarter worth $93,421,000. Franklin Resources Inc. boosted its holdings in BioNTech by 76.8% during the 2nd quarter. Franklin Resources Inc. now owns 751,998 shares of the company’s stock worth $80,065,000 after acquiring an additional 326,556 shares during the last quarter. Finally, Aberdeen Group plc grew its stake in shares of BioNTech by 87.2% in the 2nd quarter. Aberdeen Group plc now owns 721,928 shares of the company’s stock worth $76,864,000 after acquiring an additional 336,260 shares in the last quarter. Institutional investors own 15.52% of the company’s stock.

BioNTech Trading Down 1.2%

Shares of BNTX stock opened at $94.81 on Friday. The company has a 50 day moving average of $102.27 and a 200-day moving average of $105.00. The company has a quick ratio of 7.02, a current ratio of 7.12 and a debt-to-equity ratio of 0.01. BioNTech SE Sponsored ADR has a 12-month low of $81.20 and a 12-month high of $129.27. The firm has a market cap of $21.35 billion, a P/E ratio of -36.05 and a beta of 1.30.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of $0.75 by ($0.89). BioNTech had a negative net margin of 17.91% and a negative return on equity of 3.03%. The firm had revenue of $1.78 billion during the quarter, compared to analysts’ expectations of $1.21 billion. During the same quarter in the previous year, the company posted $0.81 EPS. BioNTech’s revenue for the quarter was up 22.0% on a year-over-year basis. Sell-side analysts anticipate that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. HC Wainwright reissued a “buy” rating and set a $140.00 price target on shares of BioNTech in a research report on Thursday. JPMorgan Chase & Co. dropped their target price on shares of BioNTech from $121.00 to $120.00 and set a “neutral” rating on the stock in a research report on Thursday, October 23rd. Bank of America cut their target price on BioNTech from $134.00 to $130.00 and set a “buy” rating on the stock in a research note on Wednesday, October 22nd. Jefferies Financial Group reaffirmed a “buy” rating and set a $151.00 price target on shares of BioNTech in a research report on Wednesday, December 3rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of BioNTech in a report on Tuesday, October 14th. Ten equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $137.75.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.